Web software for a molecular-AI company, through to acquisition

The brief

Molab.ai is a deep-tech company. Its product is artificial intelligence that predicts molecular properties: ADME models (absorption, distribution, metabolism and excretion) that help scientists decide which compounds are worth the lab time, alongside lead optimisation and virtual screening. The science is the hard part, and the whole story. The job of the website is to represent that credibly and then stay out of the team's way.

We worked directly with Molab.ai's founder on the software development around their web presence as the company grew. A small, highly technical team did not want to spend its time fighting a content management system, and could not afford a site that would need rebuilding the moment they scaled.

What we built

A fast, modern, fully responsive website that matched the sophistication of the technology behind it, paired with a content platform the team could operate without us.

• A responsive build that holds up from large screens down to phones, so the site reads well wherever a prospective partner or hire finds it.
• A self-service CMS, so a small team updates content directly and engineering time stays on the science rather than on copy changes.
• Built for performance and accessibility, designed in from the start rather than retrofitted later.

The point was ownership. Molab.ai could move as fast on their website as they did on their research, without a development ticket for every update.

How it shipped

We launched the site and then supported it. Ongoing management and maintenance kept it secure and current as the company scaled, so the web presence kept pace with the business instead of becoming the thing nobody had time to fix.

Because the team could run the content themselves, and the build was maintained rather than left to age, the site never became a bottleneck or a rebuild project during a period of rapid change.

The result

Through a period of rapid growth, Molab.ai's web presence kept pace, and the team ran it themselves. In July 2025, Molab.ai was acquired by Cresset, a leading drug-discovery software company, which is integrating Molab.ai's ADME modelling into its computational chemistry platform.

We will not claim a website sold a company. The science did that. Our part was making sure the software around it never held them back, through growth and into a successful acquisition.

written from project records and Cresset's public acquisition announcement, 8 July 2025